1. Autoimmune pancreatitis and minimal change nephrotic syndrome: an unusual association?

    Nephrology 20(3):225 (2015) PMID 25712557

  2. Autoimmune pancreatitis and minimal change nephrotic syndrome: an unusual association?

    Nephrology 20(3):225 (2015) PMID 25712557

  3. ONO-1301, a Sustained-Release Prostacyclin Analog, Ameliorates the Renal Alterations in a Mouse Type 2 Diabetes Model Possibly Through Its Protective Effects on Mesangial Cells.

    Acta Medica Okayama 69(1):1 (2015) PMID 25703166

    Diabetic nephropathy is the most common pathological disorder predisposing patients to end-stage renal disease. Considering the increasing prevalence of type 2 diabetes mellitus worldwide, novel therapeutic approaches are urgently needed. ONO-1301 is a novel sustained-release prostacyclin analog...
    PDF not found
  4. ONO-1301, a sustained-release prostacyclin analog, ameliorates the renal alterations in a mouse type 2 diabetes model possibly through its protective effects on mesangial cells.

    Acta Medica Okayama 69(1):1 (2015) PMID 25703166

    Diabetic nephropathy is the most common pathological disorder predisposing patients to end-stage renal disease. Considering the increasing prevalence of type 2 diabetes mellitus worldwide, novel therapeutic approaches are urgently needed. ONO-1301 is a novel sustained-release prostacyclin analog...
    PDF not found
  5. Vasohibin-1 deficiency enhances renal fibrosis and inflammation after unilateral ureteral obstruction.

    Physiological Reports 2(6) (2014) PMID 24973329

    Tubulointerstitial injuries are known to predict the deterioration of renal function in chronic kidney disease (CKD). We recently reported the protective role of Vasohibin-1(VASH-1), a negative feedback regulator of angiogenesis, in diabetic nephropathy, but its impact on tubulointerstitial inju...
  6. Vasohibin-1 deficiency enhances renal fibrosis and inflammation after unilateral ureteral obstruction.

    Physiological Reports 2(6) (2014) PMID 24973329 PMCID PMC4208642

    Tubulointerstitial injuries are known to predict the deterioration of renal function in chronic kidney disease (CKD). We recently reported the protective role of Vasohibin-1(VASH-1), a negative feedback regulator of angiogenesis, in diabetic nephropathy, but its impact on tubulointerstitial inju...
  7. Renal distribution of Vasohibin-1 in patients with chronic kidney disease.

    Acta Medica Okayama 68(4):219 (2014) PMID 25145408

    Experimental studies have demonstrated the involvement of angiogenesis-related factors in the progression of chronic kidney disease (CKD). There have so far been no reports investigating the distribution and clinical roles of Vasohibin-1 (VASH-1), a negative feedback regulator of angiogenesis, i...
    PDF not found
  8. Exacerbation of diabetic renal alterations in mice lacking vasohibin-1.

    PLoS ONE 9(9):e107934 (2014) PMID 25255225 PMCID PMC4178006

    Vasohibin-1 (VASH1) is a unique endogenous inhibitor of angiogenesis that is induced in endothelial cells by pro-angiogenic factors. We previously reported renoprotective effect of adenoviral delivery of VASH1 in diabetic nephropathy model, and herein investigated the potential protective role o...
  9. Urinary and plasma levels of vasohibin-1 can predict renal functional deterioration in patients with renal disorders.

    PLoS ONE 9(6):e96932 (2014) PMID 24915146 PMCID PMC4051610

    Vasohibin-1 (VASH-1) is a negative feedback regulator of angiogenesis, and a small vasohibin-binding protein (SVBP) serves as its secretory chaperone and contributes to its antiangiogenic effects. In the present study, we aimed to define the clinical significance of VASH-1 and SVBP in patients w...
  10. Urinary and plasma levels of vasohibin-1 can predict renal functional deterioration in patients with renal disorders.

    PLoS ONE 9(6):e96932 (2014) PMID 24915146 PMCID PMC4051610

    Vasohibin-1 (VASH-1) is a negative feedback regulator of angiogenesis, and a small vasohibin-binding protein (SVBP) serves as its secretory chaperone and contributes to its antiangiogenic effects. In the present study, we aimed to define the clinical significance of VASH-1 and SVBP in patients w...
  11. Exacerbation of diabetic renal alterations in mice lacking vasohibin-1.

    PLoS ONE 9(9):e107934 (2014) PMID 25255225 PMCID PMC4178006

    Vasohibin-1 (VASH1) is a unique endogenous inhibitor of angiogenesis that is induced in endothelial cells by pro-angiogenic factors. We previously reported renoprotective effect of adenoviral delivery of VASH1 in diabetic nephropathy model, and herein investigated the potential protective role o...
  12. Upstream stimulatory factors 1 and 2 mediate the transcription of angiotensin II binding and inhibitory protein.

    Journal of Biological Chemistry 288(26):19238 (2013) PMID 23653383 PMCID PMC3696694

    The angiotensin II type 1 receptor (AT1R)-associated protein (ATRAP/Agtrap) promotes constitutive internalization of the AT1R so as to specifically inhibit the pathological activation of its downstream signaling yet preserve the base-line physiological signaling activity of the AT1R. Thus, tissu...
  13. Upstream stimulatory factors 1 and 2 mediate the transcription of angiotensin II binding and inhibitory protein.

    Journal of Biological Chemistry 288(26):19238 (2013) PMID 23653383 PMCID PMC3696694

    The angiotensin II type 1 receptor (AT1R)-associated protein (ATRAP/Agtrap) promotes constitutive internalization of the AT1R so as to specifically inhibit the pathological activation of its downstream signaling yet preserve the base-line physiological signaling activity of the AT1R. Thus, tissu...
  14. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease.

    PLoS ONE 8(2):e56695 (2013) PMID 23431388 PMCID PMC3576368

    Klotho was originally identified in a mutant mouse strain unable to express the gene that consequently showed shortened life spans. In humans, low serum Klotho levels are related to the prevalence of cardiovascular diseases in community-dwelling adults. However, it is unclear whether the serum K...
  15. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease.

    PLoS ONE 8(2):e56695 (2013) PMID 23431388 PMCID PMC3576368

    Klotho was originally identified in a mutant mouse strain unable to express the gene that consequently showed shortened life spans. In humans, low serum Klotho levels are related to the prevalence of cardiovascular diseases in community-dwelling adults. However, it is unclear whether the serum K...
  16. Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy.

    American Journal of Physiology: Renal, Fluid & ... 303(9):F1264 (2012) PMID 22933302

    Cisplatin nephropathy can be regarded as a mitochondrial disease. Intervention to halt such deleterious injury is under investigation. Recently, the flavanol (-)-epicatechin emerges as a novel compound to protect the cardiovascular system, owing in part to mitochondrial protection. Here, we have...
  17. Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy.

    American Journal of Physiology: Renal, Fluid & ... 303(9):F1264 (2012) PMID 22933302

    Cisplatin nephropathy can be regarded as a mitochondrial disease. Intervention to halt such deleterious injury is under investigation. Recently, the flavanol (-)-epicatechin emerges as a novel compound to protect the cardiovascular system, owing in part to mitochondrial protection. Here, we have...
  18. Peritoneovenous shunting for refractory ascites results in worsening of nephrotic syndrome.

    Hepatology Research 42(10):1048 (2012) PMID 22998724

    Peritoneovenous shunt (PVS) is accepted as a treatment for refractory ascites due to liver cirrhosis. Infection is a well-known complication of shunting. However, the effects of PVS in terms of complications for renal disease are unclear. We encountered a case involving a 52-year-old man with al...
  19. Peritoneovenous shunting for refractory ascites results in worsening of nephrotic syndrome.

    Hepatology Research 42(10):1048 (2012) PMID 22998724

    Peritoneovenous shunt (PVS) is accepted as a treatment for refractory ascites due to liver cirrhosis. Infection is a well-known complication of shunting. However, the effects of PVS in terms of complications for renal disease are unclear. We encountered a case involving a 52-year-old man with al...
  20. Peritoneovenous shunting for refractory ascites results in worsening of nephrotic syndrome.

    Hepatology Research 42(10):1048 (2012) PMID 22998724

    Peritoneovenous shunt (PVS) is accepted as a treatment for refractory ascites due to liver cirrhosis. Infection is a well-known complication of shunting. However, the effects of PVS in terms of complications for renal disease are unclear. We encountered a case involving a 52-year-old man with al...